View Clinical Trial (Medical Research Study)
Evaluation Of Regional Glucose Metabolism In Striatum As Measured By [18f]-Fluorodeoxyglucose Positron Emission Tomography Following Single Oral Dose Administration Of PF-02545920 In Healthy Subjects
| City: |
|
New Haven |
| State: |
|
Connecticut |
| Zip Code: |
|
06520 |
| Conditions: |
|
Healthy |
| Purpose: |
|
We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain
called the striatum.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Healthy right-handed male and female subjects between the ages of 18 and 55 years,
inclusive
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
- An informed consent document signed and dated by the subject
- Subjects who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures
Exclusion Criteria:
- Women of reproductive potential
- History of agranulocytosis or movement disorder
- Positron Emission Tomography (PET) or Magnetic Resonance Imaging (MRI)
contraindications
|
| NCT ID: |
|
NCT01103726 |
| Primary Contact: |
|
Study Director
Pfizer CT.gov Call Center
Pfizer
Pfizer CT.gov Call Center
Phone: 1-800-718-1021
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
New Haven, Connecticut 06520
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|